Abstract
Paclitaxel is an important, recently introduced anti-neoplastic drug. Paclitaxel metabolites are virtually inactive in comparison with the parent drug. The study investigated whether phenolic antioxidants could inhibit metabolic inactivation sufficiently to increase paclitaxel effects. Cytochrome P450 (CYP)-catalysed metabolism of paclitaxel was investigated in rat and human liver microsomes. In rat microsomes, paclitaxel was metabolised mainly to C3'-hydroxypaclitaxel (C3'-OHP), less to C2-hydroxypaclitaxel (C2-OHP), di-hydroxypaclitaxel (di-OHP) and another monohydroxylated paclitaxel. In human liver microsomes, 6α-hydroxypaclitaxel (6α-OHP), formed by CYP2C8, was the main metabolite, while C3'-OHP, C2-OHP and another product different from di-OHP were minor metabolites, formed by CYP3A4. In individual human livers 6α-OHP was formed at 1.8-fold to 13-fold higher rates than C3'-OHP. Kinetic parameters (Km and Vmax) of production of various metabolites in rat and human liver microsomes revealed differences between species as well as human individual differences. Nine phenolic antioxidants ((+)-catechin, (-)-epicatechin, fisetin, gallic acid, morin, myricetin, naringenin, quercetin and resveratrol) were tested for inhibition of paclitaxel metabolism. In rat microsomes, resveratrol was more inhibitory than fisetin; the other phenolic antioxidants were without effect. In human microsomes, the inhibiting potency decreased in the order fisetin >quercetin >morin >resveratrol, while the other phenolic antioxidants were not inhibitory; the formation of 6α-OHP (CYP2C8) was generally more inhibited than that of C3'-OHP. The inhibition was mostly mixed-type. The results suggest that oral administration of some phenolic substances might increase paclitaxel blood concentrations during chemotherapy.
Similar content being viewed by others
References
Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, Walle T (1995) Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos 23:1286–1290
Aoudjit F, Vuori K (2001) Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20:4995–5004
Buening MK, Chang RL, Huang M-T, Fortner JG, Wood AW, Conney AH (1981) Activation and inhibition of benzo(a)pyrene and Aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 41:67–72
Busby WF Jr, Ackermann JM, Crespi CL (1999) Effect of methanol, ethanol, dimethylsulfoxide, and acetonitrile on activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246–249
Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I, Wright M (1994) Taxol metabolism by human liver microsomes: identification of cytochromes P450 isozymes involved in its biotransformation. Cancer Res 54:386–392
Dai R, Jacobson KA, Robinson RC, Friedman FK (1997) Differential effects of flavonoids on testosterone-metabolizing cytochrome P450s. Life Sci 61:75–80
Dantzig AH, Law KL, Cao J, Starling JJ (2001) Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 8:39–50
Desai P, Zhu Y, Duan J, Kouzi S (1996) Interspecies variation in paclitaxel metabolism in rat, guinea pig, dog, monkey and human. 7th North American ISSX Meeting, San Diego, California
De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM (2000) Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 30:857–866
Fan W (1999) Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57:1215–1221
Guengerich FP, Kim DH (1990) In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11:2275–2279
Gut I, Terelius Y, Frantík E, Linhart I, Souček P, Filipcová B, Klučková H (1993) Exposure to various benzene derivatives differently induces cytochromes P450 2B1 and P450 2E1 in rat liver. Arch Toxicol 67:237–243
Gut I, Danielová V, Holubová J, Souček P, Klučková H (2000) Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch Toxicol 74:437–446
Harris JW, Rahman A, Kim B-R, Guengerich FP, Collins JM (1994a) Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026–4035
Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV, Collins JM (1994b) Isolation, structural determination, and biological activity 6 alpha-hydroxytaxol, the principal human metabolite of Taxol. J Med Chem 37:706–709
Hertog MGL, Hollman PCH, Katan MB (1992) Content of potentially anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonly consumed in The Netherlands. J Agric Food Chem 40:2379–2383
Hertog MGL, Hollman PCH, van de Putte B (1993) Content of potentially anticarcinogenic flavonoids of tea infusions, wines, and fruit juices. J Agric Food Chem 41:1242–1246
Klener P (1995) [Taxanes—a new group of anticancer chemotherapeutic agents] (in Czech). Remedia 5:154–160
Kumar GN, Walle UK, Walle T (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J Pharm Exp Ther 268:1160–1165
Kyu-Ho HE, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, Rosenberg NGS (2000) Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 36:1565–1571
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275
Matějková Š, Gut I (2000) [Food phenolics as protective compounds against atherosclerosis] (in Czech). Remedia 10:272-281
Monsarrat B, Mariel E, Cros S, Garés M, Guénard D, Gueritte-Voegelein F, Wright M (1990) Isolation and identification of three major metabolites of Taxol in rat bile. Drug Metab Dispos 18:895–901
Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, Donehower RC, Rowinsky EK (1993) Hepatic metabolism and biliary excretion of taxol in rats and humans. J Natl Cancer Inst Monogr 15:39–46
Monsarrat B, Chtelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, Canal P (1998) Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26:229–233
Moon J-Y, Lee D-W, Park K-H (1998) Inhibition of 7-ethoxycoumarin O-deethylase activity in rat liver microsomes by naturally occurring flavonoids: structure-activity relationships. Xenobiotica 28:117–126
Nedelcheva V, Gut I, Soucek P, Frantik E (1998) Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse and human liver microsomes. Chem Biol Interact 115:53–70
Nedelcheva V, Gut I, Soucek P, Tichavská B, Tynkova L, Mraz J, Guengerich FP, Ingelman-Sundberg M (1999) Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. Arch Toxicol 73:33–40
Obermeier M, White RE, Yang CS (1995) Effects of bioflavonoids on hepatic P450 activities. Xenobiotica 25:575–584
Omura T, Sato R (1964) The carbon monooxide-binding pigment of liver microsomes: evidence for its haemoproteine nature. J Biol Chem 239:2370–2378
Palamanda J, Feng W-W, Lin C-C, Nomeir AA (2000) Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system. Drug Metab Dispos 28:38–43
Parikh A, Gillam EMJ, Guengerich FP (1997) Drug metabolism by Escherichia coli expressing human cytochrome P450. Nat Biotechnol 15:784–788
Rahman A, Korzekwa KR, Grogan J, Gonzalez J, Harris JW (1994) Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543–5546
Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646–662
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 22:665–667
Soleas GJ, Diamandis EP, Goldberg DM (1997) Wine is a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 11:287–313
Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharm Exp Ther 275:566–575
Spencer MC, Faulds D (1994) Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48:795–845
Tsyrlov IB, Mikhailenko VM, Gelboin HV (1994) Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450 s to different flavonoids. Biochim Biophys Acta 1205:325–335
Walle T (1996) Assays of CYP2C5- and CYP3A4-mediated metabolism of Taxol in vivo and in vitro. In: Johnson EF, Waterman MR (eds) Methods in enzymology. Academic, New York, p 145
Walle T, Kumar GN, McMillan JM, Thornburg KR, Walle UK (1993) Taxol metabolism in rat hepatocytes. Biochem Pharmacol 46:1661–1664
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumour agents. VI. The isolation and structure of Taxol, a novel antileucemic and antitumour agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327
Zhai S, Dai R, Friedman FK, Vestal RE (1998) Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab Dispos 26:989–992
Acknowledgements
This work was supported by grant IGA NL/6715–3 and NL/7567-3. All the experiments complied with the current laws of the Czech Republic.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Václavíková, R., Horský, S., Šimek, P. et al. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn-Schmiedeberg's Arch Pharmacol 368, 200–209 (2003). https://doi.org/10.1007/s00210-003-0781-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-003-0781-9